Physician profile
Joseph Luvisi
NPI 1043847940
$3,031.19
in general payments reported to CMS, 2019-2025
13 companies · $595 in 2025
The $595 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.14 · 2021: $180 · 2022: $452 · 2023: $777 · 2024: $1,008 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,341.57 | 2022-2025 | Clareon, Unity, Hydrus Microstent |
| Abbvie INC. | $400.61 | 2022-2025 | |
| Glaukos Corporation | $262.52 | 2022-2024 | Idose |
| Sight Sciences, INC. | $205.30 | 2021-2022 | |
| Astellas Pharma US INC | $144.09 | 2025 | Izervay |
| Genentech, INC. | $136.97 | 2023 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $131.45 | 2025 | Retina Workplace |
| Harrow Eye, LLC | $121.80 | 2024 | Tobradex St, Natacyn, Iheezo |
| Johnson & Johnson Surgical Vision, INC. | $112.33 | 2024 | Tecnis Iol |
| Dutch Ophthalmic, USA | $112.00 | 2025 | Tissueblue, Eva, Combined Machine |
| Mallinckrodt Hospital Products INC. | $28.01 | 2021 | |
| Allergan, INC. | $18.14 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Luvisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.